$140.32
1.891.37%
Últ. Act.: Oct 27, 4:02 AM
Protagonist Therapeutics (PTGX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.84 | $-0.65 | $-0.54 | $-0.62 |
| Actual | $2.29 | $0.05 | $-0.69 | $-0.62 |
| Surprise | +24.5% | +107.7% | -27.8% | 0.00% |
| Revenue | ||||
| Estimate | $213.1M | $14.0M | $14.3M | $6.5M |
| Actual | $213.5M | $56.4M | $7.4M | $4.7M |
| Surprise | +0.16% | +302.1% | -47.9% | -27.3% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.64 | $-0.48 | $-0.75 | $-0.52 |
| Revenue | ||||
| Consensus | $246.5M | $29.4M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $2.29 | $1.84 | 24.5 % |
| Q1 | May 5, 2026 | $0.05 | $-0.65 | 107.7 % |
| Q4 | Feb 25, 2026 | $-0.69 | $-0.54 | -27.8 % |
| Q3 | Nov 6, 2025 | $-0.62 | $-0.62 | 0.00 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $213.48M | $213.13M | 0.16 % |
| Q1 | May 5, 2026 | $56.37M | $14.02M | 302.1 % |
| Q4 | Feb 25, 2026 | $7.44M | $14.27M | -47.9 % |
| Q3 | Nov 6, 2025 | $4.71M | $6.48M | -27.3 % |